American Urological Association's Annual Meeting (AUA)

Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.

The CALGB prognostic risk group and subsequent life-prolonging therapies could potentially impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.

An analysis of patients with prostate cancer treated with immune checkpoint blockade indicated that microsatellite instability and mismatch repair may be indicative of response.

Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.

A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.